Immunome grants stock options and RSUs to CLO

Immunome Inc. reported equity awards to its Chief Legal Officer and General Counsel, Sandra G. Stoneman.

Rhea-AI Filing Summary

Immunome Inc. reported equity awards to its Chief Legal Officer and General Counsel, Sandra G. Stoneman. On July 23, 2026 she received stock options for 76,500 shares at a $22.01 exercise price, expiring July 22, 2036, plus 38,250 RSUs. The RSUs vest 25% annually on each grant-date anniversary, and the options vest 25% on July 23, 2027 with the balance vesting monthly over three years, in each case subject to continued service. Following the RSU award she directly holds 43,805 shares or RSUs of common stock.

Insider Trade Summary

Grant/Award: 114,750 shares

Grant/Award 2 txns

Insider Stoneman Sandra G.

Role CHIEF LEGAL OFFICER & GC

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy) F2	76,500	$0.00	$0.00
Grant/Award	Common Stock F1	38,250	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (right to buy) — 76,500 contracts (Direct); Common Stock — 43,805 shares (Direct)

Footnotes (2)

1. F1. Represents the number of shares of the Issuer's common stock ("Common Stock") underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date.
2. F2. 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.

Key Figures

Stock options granted: 76,500 shares Option exercise price: $22.01 per share RSUs granted: 38,250 units +4 more

7 metrics

Stock options granted 76,500 shares Employee stock option grant to Chief Legal Officer on July 23, 2026

Option exercise price $22.01 per share Exercise price for options expiring July 22, 2036

RSUs granted 38,250 units Restricted stock units representing common shares granted July 23, 2026

Post-award common stock holdings 43,805 shares Direct common stock/RSU holdings after RSU grant

Option expiration date July 22, 2036 Expiration of Employee Stock Option award

Initial option vesting portion 25% Options vesting on July 23, 2027, subject to continuous service

Annual RSU vesting portion 25% RSUs vesting each year on the anniversary of the grant date

Key Terms

restricted stock units ("RSUs"), contingent right to receive, continuous service

3 terms

restricted stock units ("RSUs") financial

"underlying restricted stock units ("RSUs"). Each RSU represents the contingent right"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

contingent right to receive financial

"Each RSU represents the contingent right to receive one share of Common Stock"

continuous service financial

"subject to the Reporting Person's continuous service through each such vesting date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Immunome (IMNM) grant to Sandra G. Stoneman?

Immunome granted Sandra G. Stoneman 76,500 stock options and 38,250 RSUs on July 23, 2026. The options have a $22.01 exercise price, while each RSU represents the contingent right to receive one share of common stock upon settlement.

What are the vesting terms of Sandra G. Stoneman’s new RSUs at Immunome (IMNM)?

Stoneman’s 38,250 RSUs vest and settle 25% each year on the anniversary of the grant date. Vesting is conditioned on her continuous service with Immunome through each applicable vesting date.

How do Sandra G. Stoneman’s Immunome (IMNM) stock options vest and when do they expire?

Her 76,500 stock options vest 25% on July 23, 2027, with one‑thirty‑sixth of the remaining options vesting monthly thereafter. These options carry a $22.01 exercise price and expire on July 22, 2036, subject to continued service.

How many Immunome (IMNM) shares does Sandra G. Stoneman hold after these grants?

After the July 23, 2026 RSU award, Stoneman directly holds 43,805 shares or RSUs of Immunome common stock. This figure reflects her reported direct ownership position following the new restricted stock unit grant.

Are Sandra G. Stoneman’s new Immunome (IMNM) awards linked to continued employment?

Yes. Vesting of both the 38,250 RSUs and the 76,500 stock options is subject to her continuous service. If her service ends before future vesting dates, unvested portions of these awards may not vest.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/27/2026 - 04:10 PM Accepted by SEC EDGAR 07/27/2026 - 04:10 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stoneman Sandra G.

(Last) (First) (Middle)

C/O IMMUNOME, INC.

18702 N. CREEK PARKWAY, SUITE 100

(Street)

BOTHELL WASHINGTON 98011

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Immunome Inc. [ IMNM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF LEGAL OFFICER & GC

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/23/2026		A		38,250(1)	A	$0	43,805	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$22.01	07/23/2026		A		76,500		(2)	07/22/2036	Common Stock	76,500	$0	76,500	D

Explanation of Responses:

1. Represents the number of shares of the Issuer's common stock ("Common Stock") underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date.

2. 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.

	/s/ Sandra Stoneman	07/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)